CVS Health reported first-quarter net income of $2.94 billion, a significant increase from $1.78 billion in the same period one year earlier. This surge in profits, primarily driven by its insurance arm, Aetna, highlights the ongoing process of surplus extraction within the for-profit healthcare system, even as the company's chief financial officer states that "medical costs are still too high."
The corporation surpassed Wall Street's expectations for both earnings and revenue, subsequently raising its full-year 2026 profit guidance to between $7.30 and $7.50 per share, up from a previous outlook of $7 to $7.20 per share. The projected revenue for 2026 was also increased to at least $405 billion, an upward revision from the prior forecast of at least $400 billion.
All of CVS Health's business segments—the Aetna insurer, its retail pharmacy, and health services unit—outperformed analyst predictions. The company's total revenue for the quarter reached $100.43 billion, marking a 6.2% increase from one year earlier and exceeding the $95.09 billion expected by analysts.
Surplus Extraction from Healthcare
The insurance business, Aetna, was a primary driver of this capital accumulation, generating $35.97 billion in revenue during the quarter. This figure represents an approximate 3% increase from the first quarter of 2025 and surpassed analysts' expectations of $33.28 billion. CVS CFO Brian Newman attributed the majority of the $5 billion increase in the company's overall revenue outlook to "the tail winds we're seeing" for Aetna.
Newman further explained that Aetna's performance was a result of "underlying strength and organizational changes to processes or technology that have enabled the company to 'do things more efficiently.'" This drive for efficiency directly correlates with the segment's medical benefit ratio falling to 84.6% from 87.3% one year earlier, indicating a reduction in the proportion of premiums spent on medical care, thereby increasing the surplus retained by the corporation.
The year-over-year improvement in the unit was also partly due to the absence of a premium deficiency reserve, which had been recorded in the same period in 2025. This accounting shift further bolstered reported profits for the current period.
Suppressing Medical Costs for Profit
Despite the record profits, Newman reiterated that "medical costs are still too high." He detailed CVS's internal programs designed to "take cost out of the way we do work" and improve forecasting of medical cost trends, expressing satisfaction that "we're not getting a lot of surprises." The stated objective is to continue using these tools to reduce medical costs, a strategy that prioritizes corporate profitability over comprehensive patient care.
The pharmacy and consumer wellness division reported $31.99 billion in sales, remaining relatively flat from one year earlier but still exceeding analyst expectations. This unit manages prescriptions across CVS's more than 9,000 retail pharmacies and offers services such as vaccinations and diagnostic testing.
The health services segment contributed $48.24 billion in revenue, an 11% increase from one year earlier. This segment includes Caremark, the pharmacy benefits manager, which negotiates drug discounts with manufacturers and manages formularies, effectively controlling a significant portion of the pharmaceutical supply chain to the benefit of the insurance plans it serves.
The Investor's Lens
CFO Brian Newman explicitly framed the company's strategy through the lens of capital. He stated, "From an investor lens, we said let's put out realistic, reasonable targets and then find pathways to outperform. And we did that throughout at the end of last year and the quarter." He added, "So to beat and raise, which I think is probably the fourth or fifth consecutive, it feels like we're delivering on that." This corporate executive's remarks underscore the primary directive of the for-profit healthcare system: to maximize returns for shareholders, even while acknowledging "macro uncertainty consumers are facing."
Following the earnings report, shares of CVS rose more than 7% on Wednesday, reflecting investor approval of the company's continued success in extracting wealth from the healthcare sector.